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Estrogen replacement therapy in women is associated with
improvement of cognitive deficits and reduced incidence of
Alzheimer’s disease. The present study indicates that estrogen is
neuroprotective against N-methyl-D-aspartate (NMDA)- and kain-
ate-mediated neurotoxicity, an effect mediated by tyrosine kinasey
mitogen-activated protein kinase (MAPK) pathways. Estrogen also
stimulates tyrosine phosphorylation of NMDA receptors via an src
tyrosine kinaseyMAPK pathway. Finally, estrogen-mediated en-
hancement of long-term potentiation in hippocampal slices is
mediated by activation of an src tyrosine kinase pathway. Thus,
estrogen, by activating an src tyrosine kinase and the extracellular
signal-related protein kinaseyMAPK signaling pathway, both en-
hances NMDA receptor function and long-term potentiation and
retains neuroprotective properties against excitotoxicity. These
findings warrant further evaluation of the usefulness of estrogenic
compounds for the treatment of Alzheimer’s disease and other
neurodegenerative diseases.
Estrogen replacement therapy in postmenopausal womendecreases the probability of developing Alzheimer’s disease
and slows the progress of the disease (1). In addition, estrogen
replacement therapy improves cognitive performance in women
with Alzheimer’s disease (2–4). These effects of estrogen suggest
that estrogen acts both as a cognitive enhancer and as a
neuroprotective agent. Although the mechanisms underlying
these effects remain unknown, estrogen has been shown to
increase basal synaptic responses and the magnitude of long-
term potentiation (LTP) in acute hippocampal slices (5–7).
In addition, estrogen increased both a-amino-3-hydroxy-5-
methylisoxazole propionic acid (AMPA) and N-methyl-
D-aspartate (NMDA) receptor-mediated responses in
hippocampal neurons (7–10). Such effects could account for the
estrogen-mediated cognitive improvement in humans, because
LTP is widely considered to represent a cellular model of
learning and memory (11). Recent studies have also shown that
estrogen is neuroprotective against excitotoxicity in primary
neuronal cultures (12, 13). Estrogen-mediated neuroprotection
involved the tyrosine kinaseymitogen-activated protein kinase
(MAPK) signal transduction cascade, because estrogen rapidly
activated tyrosine kinase and MAPK activity (14, 15) and
because the neuroprotective effect of estrogen against glutamate
toxicity was blocked by inhibitors of tyrosine kinases and MAPK
(16). The MAPK pathway is thought to play an important role
in the action of neurotrophins and in synaptic plasticity (17, 18),
and its activation could lead to increased expression of antiapo-
ptotic genes. A vast literature indicates that tyrosine kinase
directly phosphorylates some NMDA receptor subunits, thereby
enhancing NMDA receptor function (19–23). In addition, fyn
knockout mice have LTP impairment, suggesting that the ty-
rosine kinase pathway could be involved in LTP (24). In the
present study, we used acute and cultured hippocampal slices to
study the role of tyrosine kinaseyMAP kinase pathways in
estrogen-mediated neuroprotection against excitotoxicity, phos-
phorylation of NMDA receptors, and LTP enhancement.
Materials and Methods
Preparation of Hippocampal Slice Cultures. Transverse hippocampal
slice cultures were prepared from 7- to 10-day-old rat pups
according to standard techniques (25). Briefly, hippocampi were
dissected and sectioned transversely at 400 mm by using a
McIlwain tissue chopper (Westbury, NY) in a cutting medium
consisting of MEM (with Earle’s salts; GIBCO), 25 mM Hepes,
10 mM Tris, 10 mM glucose, and 3 mM MgCl2 (pH 7.2).
Hippocampal sections were then placed onto membrane inserts
(Millipore) in 6-well culture trays with 1 ml of growth medium
[MEM with Hanks’ salts (GIBCO)y20% (vol/vol) horse serumy3
mM glutaminey25 mM Hepesy5 mM NaHCO3y25 mM glucosey
0.5 mM ascorbatey2 mM CaCl2y2.5 mM MgCl2y0.5 mg/liter
insuliny1 mg/ml penicillin, pH 7.2].
After 7–14 days in culture, hippocampal sections were incu-
bated in serum-free medium with or without 1 nM 17-b-estradiol
(E2) for 24 h. They were then treated with 50 mM NMDA or 50
mM kainic acid (KA) for 3 h. The MAPK inhibitor PD98059 and
the tyrosine kinase inhibitor PP2 were added at a concentration
of 50 mM and 10 mM, respectively, together with E2. Cultured
slices were then incubated in serum-free medium for another
24 h. Neuronal damage was assessed by semiquantitative analysis
of propidium iodide (PI) uptake and lactate dehydrogenase
(LDH) assay (26).
Immunoblotting. For Western blots, cultured hippocampal slices
were collected and sonicated in 10 mM TriszHCl buffer (pH 7.4)
containing 0.32 M sucrose, 2 mM EDTA, 2 mM EGTA, and 0.1
mM leupeptin. Aliquots of homogenates (30–40 mg protein per
lane) were diluted with equal volumes of 23 sample buffer [2%
(vol/vol) SDSy50 mM TriszHCl, pH 6.8y10% (vol/vol) 2-mer-
captoethanoly10% (vol/vol) glyceroly0.1% bromophenol blue].
After heating samples at 90–100°C for 5 min, proteins were
subjected to SDSyPAGE (27) and transferred onto nitrocellu-
lose membranes (28). GluR1 proteins were probed with a
C-terminal domain antibody (C-Ab, 1:500; Chemicon). Anti-
NR2 and anti-phosphotyrosine antibodies were obtained from
Chemicon and Upstate Biotechnology (Lake Placid, NY), re-
spectively. Immunoblots were scanned, and the digitized images
were analyzed quantitatively by densitometry with the IMAGE-
QUANT program providing peak areas and apparent molecular
masses.
Abbreviations: NMDA, N-methyl-D-aspartate; KA, kainic acid; AMPA, a-amino-3-hydroxy-
5-methylisoxazole propionic acid; MAPK, mitogen-activated protein kinase; E2, 17-b-
estradiol; LDH, lactate dehydrogenase; PI, propidium iodide; LTP, long-term potentiation;
EPSP, excitatory postsynaptic potential.
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Immunoprecipitation. Hippocampal slice cultures were removed
from the membrane insert and placed in a microfuge tube with
200 ml of ice-cold homogenization buffer [20% (volyvol) sucrose
in PBS with 3.0 mM EGTA] and sonicated. Samples were
centrifuged at 14,000 3 g for 15–20 min. The supernatant was
discarded; the pellet was resuspended in 100 mM EGTA in
distilled water and centrifuged again as above. The pellet was
resuspended in Tris-acetate (100 mM; pH 7.4) containing 100
mM EGTA and centrifuged again. The supernatant was dis-
carded, and this last step was repeated at least once. The final
pellet was resuspended in the Tris-acetate buffer and frozen at
270°C until used. Membranes fractions ('300 mg of protein)
were lysed in PBS containing protease inhibitors (0.1 mM
PMSFy1 mg/ml pepstatin Ay1 mg/ml leupeptin) and 2 mM
EDTA. Membranes were then sonicated and centrifuged at 4°C
for 10 min at 100,000 3 g. Membranes fractions were resus-
pended in lysis buffer containing 1% (volyvol) SDS and heated
at 95°C for 5 min, followed by dilution in four volumes of cold
lysis buffer containing 2% (volyvol) Triton X-100. Insoluble
materials were removed by centrifugation at 100,000 3 g for 10
min. Protein A-agarose (Upstate Biotechnology)yanti-NR2AyB
antibody mixtures (3 mg each) were added to the supernatant and
incubated with gentle agitation overnight at 4°C. Immunoreac-
tive complexes were recovered by centrifugation at 14,000 3 g for
Fig. 1. Effects of E2 on KA- and NMDA-elicited neurotoxicity. Hippocampal slices were prepared as described in Materials and Methods and were maintained
in cultures for 10–14 days. They were treated with NMDA or KA (50 mM) for 3 h and returned to normal medium for 24 h. When present, E2 was added at 1 nM
24 h before NMDA or KA and was present for the duration of the experiment. (A) PI uptake in control, 24 h after a 3-h treatment with KA (50 mM) in the absence
or presence of E2. DG, dentate gyrus. (B) LDH activity in medium measured in control (Cont), 48 h after treatment with E2 (E2), 24 h after KA or NMDA treatment
in the absence (KyNMDA) or presence of E2 (K1E2yNMDA1E2). Results are means 6 SEM of six to eight experiments. *, P , 0.001 compared with KA or NMDA
(Student’s t test).
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5 s. The pellets were washed first with lysis buffer [containing 2%
(volyvol) Triton X-100] and then with PBS. Proteins were eluted
finally in 23 sample buffer [13 sample buffer consists of 2%
(volyvol) SDS, 50 mM TriszHCl (pH 6.8), 10% (volyvol) 2-mer-
captoethanol, 10% (volyvol) glycerol, and 0.1% bromophenol
blue] and incubated at 95°C for 5 min. Immunoprecipitated
proteins were subjected to SDSyPAGE with 8% polyacrylamide
gels, and to immunoblotting as described above.
Electrophysiology in Acute Hippocampal Slices. Transverse hip-
pocampal slices (400-mm-thick) were prepared from adult Sprague–
Dawley rats with a McIlwain tissue chopper. Slices were immedi-
ately placed in ice-cold cutting buffer containing (in mM) NaCl
(124), KCl (3), KH2PO4 (1.25), CaCl2 (1), MgCl2 (3), NaHCO3 (26),
glucose (10), and L-ascorbate (2). Slices were then transferred to an
interface chamber constantly oxygenated with a 95% O2: 5% CO2
mixture and perfused with an artificial cerebrospinal fluid contain-
ing (in mM) NaCl (124), KCI (3), KH2PO2, (1.25), CaCl2 (3), MgCl2
(1), NaHCO3 (26), glucose (10), and L-ascorbate (2). Perfusion was
stopped when recordings began, such that all experiments were
done under static bath conditions, allowing for the application of
small volumes of drugs.
Recording of extracellular field potentials evoked in CA1 after
electrical stimulation of the Schaffer collateral pathway was
performed with a bipolar stimulating electrode and a glass
recording electrode positioned in stratum radiatum. Stimulus
intensity was set to approximately one-third of the intensity
required to evoke a population spike, and responses were evoked
every 30 s (0.033 Hz; pulse duration of 0.1 ms). LTP was induced
by a high frequency burst (100 Hz for 1 s). All drugs were applied
directly into the recording chamber.
Results
Estrogen-Mediated Neuroprotection Against Excitotoxicity in Hip-
pocampal Slice Cultures. Treatment of hippocampal slice cultures
with 50 mM KA or NMDA for 3 h resulted in neuronal
degeneration assessed by both the extent of PI uptake and LDH
release in the culture medium (Fig. 1). Control cultures showed
no obvious PI uptake, whereas KA- or NMDA-treated cultures
Fig. 2. Effects of tyrosine kinase inhibitors on E2-mediated neuroprotection
against KA and NMDA neurotoxicity. Hippocampal slices were treated as
described for Fig. 1. PP2 (10 mM) or PD98059 (50 mM) was added at the same
time and for the same duration as E2. Toxicity was assessed by measuring LDH
release in the medium 24 h after KA or NMDA treatment. Results are means 6
SEM of six to eight experiments. *, P , 0.001 compared with KA or NMDA
alone; §, not significantly different from NMDA alone; #, not significantly
different from KA alone (Student’s t test).
Fig. 3. Effects of tyrosine kinase inhibitors on E2-mediated protection of the
C-terminal domain of GluR1 or NR2 subunits against NMDA-elicited trunca-
tion. Hippocampal slices were treated with NMDA (50 mM) for 3 h. E2 and PP2
or PD98059 were added as described for Fig. 2. Immunoblots were performed
as described in Materials and Methods and were labeled with antibodies
against the C-terminal domains of GluR1 (105 kDa) or NR2 (170 kDa) subunits.
(A) Representative blot, with the order of treatment as indicated in B. (B)
Quantification of blots similar to the ones shown in A. Results are expressed
as the percentage of values found in control conditions and are means 6 SEM
of six to eight experiments.
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had intense and sustained PI uptake, particularly in CA1 and
CA3 areas and dentate gyrus. Pretreatment of cultures with 1
nM E2 for 24 h significantly decreased KA- (Fig. 1 A) or
NMDA-induced PI uptake (not shown). LDH activity in the
medium was markedly increased 24 h after KA or NMDA (Fig.
1B) treatment. Pretreatment with 1 nM E2 significantly reduced
LDH release in the medium with both excitotoxins (Fig. 1B). The
effect of E2 was similar whether cultures were pretreated for 24 h
or for 10 min, suggesting that the neuroprotection effect did not
require transcriptional activation. Because estrogen had been
shown to protect neuronal cultures against glutamate toxicity via
the activation of the tyrosine kinaseyMAPK pathway (13, 16),
we tested the effects of an inhibitor of src tyrosine kinase, PP2,
and an inhibitor of the MAPK kinase, PD98059, on control and
E2-treated cultured hippocampal slices (Fig. 2). Treatment with
the inhibitors alone did not modify PI uptake or LDH release in
the medium. Both inhibitors completely blocked E2-mediated
neuroprotection assessed with PI uptake (not shown) or LDH
release (Fig. 2).
Estrogen-Mediated Modifications of AMPA and NMDA Receptor Sub-
units. Treatment of hippocampal slice cultures with NMDA (50
mM) for 3 h produced a significant decrease in GluR1 and NR2
immunoreactivity in Western blots labeled with antibodies
recognizing their C-terminal domains (Fig. 3). We discussed
elsewhere the evidence indicating that the decrease in immu-
noreactivity is caused by calpain-mediated truncation of the
C-terminal domains of several AMPA and NMDA receptor
subunits (29, 30). Pretreatment with E2 did not modify the
amount of GluR1 or NR2 subunits but completely prevented
NMDA-induced decrease in both subunits. Combined treatment
of cultures with E2 and PD98059 or PP2 completely blocked the
effects of E2 on GluR1 and NR2 subunits (Fig. 3). Similar effects
were obtained with KA treatment (not shown). To evaluate
E2-induced changes in NMDA receptor subunit properties
further, membrane preparations from hippocampal slice cultures
incubated under various conditions were solubilized, and
NMDA receptors were immunoprecipitated with antibodies
against the C-terminal domain of NR2 subunits. Western blots
were then stained with either anti-NR2 antibodies or anti-
phosphotyrosine antibodies (Fig. 4 A and B). As shown previ-
ously, anti-phosphotyrosine antibodies labeled a band with an
apparent molecular mass of 170 kDa that corresponds to NR2
subunits (ref. 31 and R.B. and M.B., unpublished work). NMDA
treatment resulted in a large decrease in NR2 subunits stained
with anti-NR2 antibodies, whereas it had no effect on the
170-kDa band stained with anti-phosphotyrosine antibodies.
Pretreatment of hippocampal slice cultures with E2 did not
modify the amount of NR2 subunits labeled with anti-NR2
antibodies but increased that labeled with anti-phosphotyrosine
antibodies. However, pretreatment with E2 did prevent NMDA-
induced decrease in the amount of NR2 subunits labeled with the
Fig. 4. Effects of E2 on NR2 subunits of NMDA receptors. Hippocampal slices
were treated as described for Fig. 3. At the end of the experiments, membrane
fractions were prepared, and proteins were immunoprecipitated with anti-
NR2AyB antibodies. Immunoblots were then stained with antibodies against
anti-NR2AyB (A) or anti-phosphotyrosine (B). Alternatively, slices were
incubated for 30 min with E2 in the presence or absence of PP2 (10 mM).
Immunoblots of samples from membrane fractions were stained with anti-
phosphotyrosine antibodies and quantified as described (C). (A Upper) Rep-
resentative Western blot. (A Lower) Quantitative analysis of blots similar to
the blot shown in A Upper. Results are expressed as percentage of values
found in control conditions (Cont) and are means 6 SEM of four experiments.
*, P , 0.001 as compared with control (Student’s t test). (B Upper) Represen-
tative Western blot. (B Lower) Quantitative analysis of blots similar to the blot
shown in B Upper. Results are expressed as percentage of values found in
control conditions (Cont) and are means 6 SEM of four experiments. *, P ,
0.001 compared with control (Student’s t test). (C) Quantitative analysis of
immunoblots of membrane fractions stained with anti-phosphotyrosine an-
tibodies. Results are expressed as percentage of values found in control
conditions (Cont) and are means 6 SEM of four experiments. *, P , 0.001
compared with control (Student’s t test).
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anti-NR2 antibodies. NMDA treatment did not decrease the
amount of NR2 labeled with anti-phosphotyrosine antibodies.
Finally, E2 treatment of hippocampal slice cultures for 30 min
significantly increased tyrosine phosphorylation of NR2 sub-
units as evidenced by the increase in immunolabeling of the
170-kDa band in membrane fractions (Fig. 4C). This effect was
blocked completely by PP2, whereas PP2 alone did not modify
the extent of immunolabeling.
Effects of E2 on LTP in Acute Hippocampal Slices. As previously
reported (5, 7), incubation of acute hippocampal slices with 1 nM
E2 resulted in a rapid increase in excitatory postsynaptic poten-
tial (EPSP) amplitude evoked in CA1 by electrical stimulation of
the Schaffer collateral pathway (Fig. 5). To evaluate the effects
of E2 on the magnitude of LTP, the intensity of stimulation was
decreased to reset baseline values to the predrug level immedi-
ately before delivering the high frequency stimulation train.
Under these conditions, E2 also resulted in an increase in the
amplitude of LTP (Fig. 5; Table 1). When similar experiments
were performed in the presence of the src inhibitor PP2, E2 no
longer increased basal EPSP amplitude, nor did it increase LTP
magnitude (Fig. 5; Table 1). Note that, under the same condi-
tions, PP2 alone did not significantly influence LTP magnitude
(Table 1).
Discussion
The present results indicate that E2 exerts a multiplicity of
effects on the properties of glutamate ionotropic receptors, LTP,
and excitotoxicity through the activation of the tyrosine kinasey
MAPK kinase pathway. First, we showed that E2 treatment of
hippocampal slice cultures produced a significant degree of
protection against both KA and NMDA neurotoxicity. This
effect was observed whether the steroid was added 24 h or 10 min
before the excitotoxins, suggesting that the neuroprotective
effect was probably not caused by the activation of a nuclear
receptor and the activation of genes with estrogen regulatory
elements. E2 neuroprotective effect was blocked completely by
an inhibitor of src tyrosine kinase or of the MAPK kinase,
suggesting that the effect is caused by the activation of a pathway
that is shared with a variety of neurotrophic factors. Our results
are in good agreement with a recent report indicating that
estrogen neuroprotection against glutamate toxicity in cortical
neurons in cultures is mediated by the activation of the same
pathways (16). Likewise, our results are in good agreement with
those of Singh et al. (18), who showed that estrogen rapidly
activates src tyrosine kinase and the MAPK kinase pathway in
cortical organotypical cultures.
We previously reported that NMDA or KA treatment of
hippocampal slice cultures is accompanied by calpain activation
and the resulting truncation of the C-terminal domains of several
subunits of AMPA and NMDA receptors (29, 30). Although the
Fig. 5. Effects of an src inhibitor on E2-mediated enhancement of EPSP amplitude and degree of LTP in acute hippocampal slices. Acute hippocampal slices
were prepared as described in Materials and Methods. A stimulating electrode was located in CA3, and a recording electrode was located in stratum radiatum
of CA1. Extracellular EPSPs were evoked by stimulation every 30 s, and the amplitude of the EPSP was measured. After a stable baseline was recorded, PP2 (10
mM) was added at the indicated time. Likewise, E2 (1 nM) was added at the indicated time. After resetting the stimulation intensity to obtain an EPSP of the same
amplitude as before treatment with PP2 or E2, high frequency stimulation was delivered, and low frequency stimulation was resumed. Results are expressed as
percentage of predrug values and are means 6 SEM of 6–10 experiments. HFS, high-frequency stimulation.
Table 1. Effects of E2 and PP2 on baseline responses and LTP
amplitude measured 30 min after tetanus
Treatment (no.)
Baseline response,
%
LTP amplitude,
%
Control (10) 101 6 1 163 6 3
E2 (10) 150 6 2* 204 6 5*
PP2 (6) 107 6 2 184 6 7
PP2 1 E2 (7) 115 6 3† 172 6 4†
See legend to Fig. 5. Results for the baseline response represent the
amplitude of EPSPs before high frequency stimulation and are expressed as
percentage of the predrug levels. LTP amplitudes represent the amplitudes of
EPSPs measured 30 min after high frequency stimulation and are expressed as
percentage of the average values measured immediately before high fre-
quency stimulation. Data are means 6 SEM of the indicated number of
experiments. *, P , 0.05 compared with the respective control values. †, P ,
0.05 when compared to E2 alone but not significant from control (Student’s
t test).
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functional significance of the truncation is not clear at the
moment, we also found that phosphorylation of the subunits
protects them from calpain-mediated truncation (32). Moreover,
we demonstrated that src-mediated phosphorylation of NR2
subunits of NMDA receptors completely protects the subunits
from such truncation (R.B., Y. Rong, and M.B., unpublished
work). The results we observed in this study indicate clearly that
estrogen treatment of hippocampal slice cultures results in
activation of src tyrosine kinase and tyrosine phosphorylation of
NR2A subunits and protects them from calpain-mediated trun-
cation of their C-terminal domains that takes place after exci-
totoxin treatment. Numerous reports have shown that NR2
subunits of NMDA receptors are a major substrate for src
tyrosine kinases (19–23). Our results imply that MAPK kinase
could also phosphorylate NR2 subunits, because PD98059 is an
inhibitor more specific for MAPK than for src tyrosine kinases
that also prevents estrogen-mediated blockade of calpain trun-
cation of NR2 subunits. Interestingly, estrogen also protected the
C-terminal domain of GluR1 receptors from KA- or NMDA-
induced truncation, an effect also blocked by inhibitors of src
tyrosine kinase or MAPK kinase. Because GluR1 is not known
to be a substrate of tyrosine kinases, it is possible that tyrosine
kinases activate other protein kinases capable of phosphorylat-
ing AMPA receptor subunits and thereby of protecting them
from calpain-mediated truncation of their C-terminal domains.
Estrogen had been shown to enhance both AMPA and NMDA
receptor-mediated responses as well as to enhance the degree of
LTP elicited in CA1 pyramidal neurons by high frequency
stimulation of the Schaffer collateral pathway (5–7). Our results
confirmed both the estrogen-induced increase in the amplitude
of AMPA receptor-mediated EPSP and in the degree of LTP in
hippocampal slices. Both effects of estrogen were blocked com-
pletely by a src inhibitor. As mentioned above, NMDA receptors
are a major substrate for src tyrosine kinase, and src-mediated
tyrosine phosphorylation of NR2 subunits has been shown to
increase NMDA receptor-mediated responses (19–23, 33, 34).
Thus, the estrogen effect on LTP is likely caused by the
activation of src and the tyrosine phosphorylation of NR2
subunits. The effect of estrogen on basal EPSP has been
proposed to be caused by the activation of adenylate cyclase (10).
Our results would imply that the tyrosine kinase pathway might
be coupled to the adenylate cyclase pathway. Further studies
should be directed at this issue.
Our results then indicate that estrogen, by activating the
tyrosine kinaseyMAPK pathways, exerts both a ‘‘cognitive’’
effect and a neuroprotective effect. The estrogen-mediated
enhancement of the degree of LTP as a result of the activation
of this pathway fits well with several data indicating that this
pathway is important for LTP (35–37). Thus, fyn knockout
mice have LTP and learning impairment, whereas MAPK
inhibitors impair spatial learning (38). However, it is important
to note that, under our conditions, the inhibitor of src tyrosine
kinase PP2 did not modify the degree of LTP and that src
knockout mice have normal LTP (24). Thus, different tyrosine
kinases might play different roles in regulating NMDA recep-
tors and LTP characteristics. Although the estrogen-mediated
increase in NMDA receptor function resulting from tyrosine
phosphorylation should have been expected to enhance
NMDA neurotoxicity, the activation of the MAPK pathway
provided neuroprotection presumably by activating neuropro-
tective cascades downstream from NMDA receptor activation.
This idea also fits well with the notion that estrogen and
neurotrophins might share similar signaling pathways (18).
Our results therefore warrant further studies to evaluate the
usefulness of estrogenic compounds for the treatment of
Alzheimer’s disease and other neurodegenerative diseases.
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